Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charlie Gourley

Showing results (51-60 of 145) with videos related to

Pageof 15
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Physician-reported patient involvement and treatment decisions in first-line ovarian cancer in the USA and EuropeKathleen N Moore, Mansoor R Mirza, Charlie Gourley, et al.
The EMBO Journal|March 6, 2020
Infection-driven activation of transglutaminase 2 boosts glucose uptake and hexosamine biosynthesis in epithelial cellsBenoit Maffei, Marc Laverrière, Yongzheng Wu, et al.
American Journal of Obstetrics and Gynecology|May 6, 2019
Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapseRobert L Hollis, Juliet Carmichael, Alison M Meynert, et al.
Gynecologic Oncology|December 4, 2018
Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictorsBarbara Stanley, Robert L Hollis, Hugo Nunes, et al.
Cancers|November 27, 2021
Clinicopathological Determinants of Recurrence Risk and Survival in Mucinous Ovarian CarcinomaRobert L Hollis, Lorna J Stillie, Samantha Hopkins, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2010
First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC seriesRoshan Agarwal, Charlie Gourley, Timothy J Perren, et al.
Gynecologic Oncology Reports|July 11, 2022
Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancerJeffrey C H Goh, Charlie Gourley, David S P Tan, et al.
British Journal of Cancer|December 10, 2019
Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumoursCorran Roberts, Victoria Y Strauss, Sylwia Kopijasz, et al.
BMC Cancer|January 5, 2018
Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrationsRobert L Hollis, Alison M Meynert, Michael Churchman, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 22, 2014
Using serum CA125 to assess the activity of potential cytostatic agents in ovarian cancerMarcia R Hall, Ann Petruckevitch, Joanna Pascoe, et al.
Pageof 15

Showing results (51-60 of 145) with videos related to

Sort By:
Pageof 15
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Physician-reported patient involvement and treatment decisions in first-line ovarian cancer in the USA and EuropeKathleen N Moore, Mansoor R Mirza, Charlie Gourley, et al.
The EMBO Journal|March 6, 2020
Infection-driven activation of transglutaminase 2 boosts glucose uptake and hexosamine biosynthesis in epithelial cellsBenoit Maffei, Marc Laverrière, Yongzheng Wu, et al.
American Journal of Obstetrics and Gynecology|May 6, 2019
Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapseRobert L Hollis, Juliet Carmichael, Alison M Meynert, et al.
Gynecologic Oncology|December 4, 2018
Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictorsBarbara Stanley, Robert L Hollis, Hugo Nunes, et al.
Cancers|November 27, 2021
Clinicopathological Determinants of Recurrence Risk and Survival in Mucinous Ovarian CarcinomaRobert L Hollis, Lorna J Stillie, Samantha Hopkins, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2010
First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC seriesRoshan Agarwal, Charlie Gourley, Timothy J Perren, et al.
Gynecologic Oncology Reports|July 11, 2022
Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancerJeffrey C H Goh, Charlie Gourley, David S P Tan, et al.
British Journal of Cancer|December 10, 2019
Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumoursCorran Roberts, Victoria Y Strauss, Sylwia Kopijasz, et al.
BMC Cancer|January 5, 2018
Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrationsRobert L Hollis, Alison M Meynert, Michael Churchman, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 22, 2014
Using serum CA125 to assess the activity of potential cytostatic agents in ovarian cancerMarcia R Hall, Ann Petruckevitch, Joanna Pascoe, et al.
Pageof 15